TransCode Therapeutics Return on Equity

TransCode Therapeutics (RNAZ) currently reports a ROE of 226.14%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore TransCode Therapeutics's ROE history and peer comparisons.

TransCode Therapeutics's ROE of 226.14% is higher than the Healthcare sector average of 11.15%. That is roughly 1927.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but TransCode Therapeutics's current 226.14% should be judged against Healthcare norms (sector average: 11.15%) and against RNAZ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 226.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for TransCode Therapeutics, and consider following RNAZ for alerts when major investors trade the stock.

TransCode Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 226.14% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNAZ with unrelated industries.